Skip to main content
PMC home page
Gut logoLink to Gut
. 1989 May;30(5):675–679. doi: 10.1136/gut.30.5.675

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.

S S Rao 1, S A Dundas 1, C D Holdsworth 1, P A Cann 1, K R Palmer 1, C L Corbett 1
PMCID: PMC1434223  PMID: 2567266

Abstract

Olsalazine (2 g/day) and sulphasalazine (3 g/day) were compared in a double blind three centre trial in 37 patients presenting with first attack of distal colitis. Sigmoidoscopic appearances, rectal biopsies, and symptom and stool diary records were used to assess benefit and adverse effects. Both groups showed a similar decrease in stool frequency (p less than 0.001). The proportion of unformed stools was also decreased, but to a lesser extent (p less than 0.05) in those taking olsalazine (78% v 55%; p less than 0.001) compared with those taking sulphasalazine (72% v 28%; p less than 0.001). There was a diminution in the proportion of stools containing blood in both groups (olsalazine: 61% v 22%; p less than 0.001/sulphasalazine: 67% v 37%; p less than 0.001). Sigmoidoscopic and histological appearances and clinical activity improved significantly and to a similar extent in both groups. Intolerance was encountered in two patients on olsalazine and four on sulphasalazine; intolerance to sulphasalazine being even higher (five of seven patients) in a preliminary study using a dose of sulphasalazine releasing the same amount of 5-aminosalicylic acid as 2 g olsalazine. Olsalazine was at least as effective as sulphasalazine in the treatment of new patients with distal colitis, and in a dose releasing an equivalent amount of 5-aminosalicylic acid was better tolerated.

Full text

PDF
675

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
  4. Dew M. J., Hughes P., Harries A. D., Williams G., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):1012–1012. doi: 10.1136/bmj.285.6347.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ireland A., Mason C. H., Jewell D. P. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988 Jun;29(6):835–837. doi: 10.1136/gut.29.6.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  7. Meyers S., Sachar D. B., Present D. H., Janowitz H. D. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987 Dec;93(6):1255–1262. doi: 10.1016/0016-5085(87)90253-8. [DOI] [PubMed] [Google Scholar]
  8. Miyachi Y., Yoshioka A., Imamura S., Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut. 1987 Feb;28(2):190–195. doi: 10.1136/gut.28.2.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rao S. S., Cann P. A., Holdsworth C. D. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol. 1987 Apr;22(3):332–336. doi: 10.3109/00365528709078600. [DOI] [PubMed] [Google Scholar]
  10. Rao S. S., Read N. W., Holdsworth C. D. Influence of olsalazine on gastrointestinal transit in ulcerative colitis. Gut. 1987 Nov;28(11):1474–1477. doi: 10.1136/gut.28.11.1474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sandberg-Gertzén H., Järnerot G., Bukhave K., Lauritsen K., Rask-Madsen J. Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy. Gut. 1986 Nov;27(11):1306–1311. doi: 10.1136/gut.27.11.1306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sandberg-Gertzén H., Järnerot G., Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986 Apr;90(4):1024–1030. doi: 10.1016/0016-5085(86)90882-6. [DOI] [PubMed] [Google Scholar]
  13. Selby W. S., Barr G. D., Ireland A., Mason C. H., Jewell D. P. Olsalazine in active ulcerative colitis. Br Med J (Clin Res Ed) 1985 Nov 16;291(6506):1373–1375. doi: 10.1136/bmj.291.6506.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sharon P., Ligumsky M., Rachmilewitz D., Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978 Oct;75(4):638–640. [PubMed] [Google Scholar]
  15. Sircar J. C., Schwender C. F., Carethers M. E. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170–172. doi: 10.1016/0006-2952(83)90673-1. [DOI] [PubMed] [Google Scholar]
  16. TRUELOVE S. C., RICHARDS W. C. Biopsy studies in ulcerative colitis. Br Med J. 1956 Jun 9;1(4979):1315–1318. doi: 10.1136/bmj.1.4979.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. TRUELOVE S. C., WITTS L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Willoughby C. P., Aronson J. K., Agback H., Bodin N. O., Truelove S. C. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut. 1982 Dec;23(12):1081–1087. doi: 10.1136/gut.23.12.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES